Molecular imaging biomarkers for immune checkpoint inhibitor therapy

Pim P. van de Donk; Laura Kist de Ruijter; Marjolijn N. Lub-de Hooge; Adrienne H. Brouwers; Anthonie J. van der Wekken; Sjoukje F. Oosting; Rudolf S. N. Fehrmann; Derk Jan A. de Groot; Elisabeth G. E. de Vries

doi:10.7150/thno.38339

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

Pim P. van de Donk, Laura Kist de Ruijter, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Anthonie J. van der Wekken, Sjoukje F. Oosting, Rudolf S. N. Fehrmann, Derk Jan A. de Groot, Elisabeth G. E. de Vries^*

^*Corresponding author for this work

Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Research output: Contribution to journal › Review article › peer-review

79 Citations (Scopus)

361 Downloads (Pure)

Abstract

Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients’ immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with ¹⁸F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.

Original language	English
Pages (from-to)	1708-1718
Number of pages	11
Journal	Theranostics
Volume	10
Issue number	4
DOIs	https://doi.org/10.7150/thno.38339
Publication status	Published - 2020

Keywords

molecular imaging
biomarkers
positron emitting tomography
immune checkpoint inhibitor
immunotherapy
METASTATIC MELANOMA PATIENTS
LIGAND 1 EXPRESSION
REGULATORY T-CELLS
PD-L1 EXPRESSION
F-18-FDG PET/CT
RESPONSE EVALUATION
METABOLIC-ACTIVITY
CANCER-PATIENTS
TUMOR RESPONSE
BREAST-CANCER

Access to Document

10.7150/thno.38339Licence: CC BY

Molecular imaging biomarkers for immune checkpointFinal publisher's version, 445 KBLicence: CC BY

Handle.net

Persistent link

Cite this

@article{0b74f3c061ac45df84aba6696ad7c46f,

title = "Molecular imaging biomarkers for immune checkpoint inhibitor therapy",

abstract = "Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients{\textquoteright} immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with 18F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.",

keywords = "molecular imaging, biomarkers, positron emitting tomography, immune checkpoint inhibitor, immunotherapy, METASTATIC MELANOMA PATIENTS, LIGAND 1 EXPRESSION, REGULATORY T-CELLS, PD-L1 EXPRESSION, F-18-FDG PET/CT, RESPONSE EVALUATION, METABOLIC-ACTIVITY, CANCER-PATIENTS, TUMOR RESPONSE, BREAST-CANCER",

author = "{van de Donk}, {Pim P.} and {Kist de Ruijter}, Laura and {Lub-de Hooge}, {Marjolijn N.} and Brouwers, {Adrienne H.} and {van der Wekken}, {Anthonie J.} and Oosting, {Sjoukje F.} and Fehrmann, {Rudolf S. N.} and {de Groot}, {Derk Jan A.} and {de Vries}, {Elisabeth G. E.}",

note = "{\textcopyright} The author(s).",

year = "2020",

doi = "10.7150/thno.38339",

language = "English",

volume = "10",

pages = "1708--1718",

journal = "Theranostics",

issn = "1838-7640",

publisher = "IVYSPRING INT PUBL",

number = "4",

}

TY - JOUR

T1 - Molecular imaging biomarkers for immune checkpoint inhibitor therapy

AU - van de Donk, Pim P.

AU - Kist de Ruijter, Laura

AU - Lub-de Hooge, Marjolijn N.

AU - Brouwers, Adrienne H.

AU - van der Wekken, Anthonie J.

AU - Oosting, Sjoukje F.

AU - Fehrmann, Rudolf S. N.

AU - de Groot, Derk Jan A.

AU - de Vries, Elisabeth G. E.

N1 - © The author(s).

PY - 2020

Y1 - 2020

N2 - Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients’ immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with 18F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.

AB - Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients’ immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with 18F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.

KW - molecular imaging

KW - biomarkers

KW - positron emitting tomography

KW - immune checkpoint inhibitor

KW - immunotherapy

KW - METASTATIC MELANOMA PATIENTS

KW - LIGAND 1 EXPRESSION

KW - REGULATORY T-CELLS

KW - PD-L1 EXPRESSION

KW - F-18-FDG PET/CT

KW - RESPONSE EVALUATION

KW - METABOLIC-ACTIVITY

KW - CANCER-PATIENTS

KW - TUMOR RESPONSE

KW - BREAST-CANCER

U2 - 10.7150/thno.38339

DO - 10.7150/thno.38339

M3 - Review article

C2 - 32042331

SN - 1838-7640

VL - 10

SP - 1708

EP - 1718

JO - Theranostics

JF - Theranostics

IS - 4

ER -

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this